Diagnostics company LabCorp has agreed to buy medical and pharmaceutical research company Covance — one of the biggest such companies in the industry — for $6.1 billion in cash and stock, according to ...
BURLINGTON, N.C.--(BUSINESS WIRE)-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today unveiled its latest solution for decentralized ...
LabCorp reported net revenues of nearly $9.5 billion for 2016 through the contributions of 52,000 employees in approximately 60 countries. To learn more about LabCorp, visit www.labcorp.com, and to ...
Laboratory Corporation of America Holdings LH or LabCorp has been gaining from strength in its Covance Drug Development business. The company’s acquisitions of Ovia Health and Personal Genome ...
Covance shareholders to receive cash and LabCorp shares currently valued at $105.12 per Covance share Combination creates comprehensive healthcare diagnostics company offering customers end-to-end ...
LabCorp will expand its global nonclinical drug development capabilities through a pair of deals in which its Covance Drug Development segment will acquire Envigo’s nonclinical research services ...
LabCorp acquired outsourcing company Sciformix and plans to integrate it into its Covance drug-development arm. The terms of the deal were not disclosed. The purchase of Sciformix, which focuses on ...
BURLINGTON – John Ratliff, a former senior executive at Quintiles who left in 2013 and became head of LabCorp’s Covance unit in 2016 to take on Quintiles (now Iqvia) as a clinical research ...
BURLINGTON – Global life science giant LabCorp has closed on its $485 million deal with Envigo, a research firm, and has borrowed $850 million to help finance it. As part of the LabCorp-Envigo asset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback